{"nctId":"NCT01680159","briefTitle":"A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis","startDateStruct":{"date":"2012-07"},"conditions":["Plaque Psoriasis","Psoriatic Arthritis","Pustular Psoriasis (Excluding a Localized)","Psoriatic Erythroderma"],"count":51,"armGroups":[{"label":"TA-650","type":"EXPERIMENTAL","interventionNames":["Drug: TA-650"]}],"interventions":[{"name":"TA-650","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have already been diagnosed as having plaque psoriasis, psoriatic arthritis, pustular psoriasis (excluding a localized), or psoriatic erythroderma.\n* Patients in whom effect of the treatment was confirmed for a certain period after the start of administration of RemicadeÂ® at 5 mg/kg at every 8 weeks but decreased thereafter.\n\nExclusion Criteria:\n\n* Patients who have guttate psoriasis.\n* Patients who have drug-induced psoriasis\n* Patients who have previously used any other biological products than infliximab.\n* Patients who have a concomitant diagnosis, or a history within 6 months prior to provisional enrollment, of serious infections that need hospitalization.\n* Patients who have a concomitant diagnosis, or a history within 6 months prior to provisional enrollment, of opportunistic infections\n* Female patients who are pregnant, breast-feeding, or possibly pregnant.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Achieving 75% Improvement in the Psoriasis Area and Severity Index (PASI) Score","description":"The investigator or the subinvestigator examined the head, trunk, and upper and lower limbs, and assessed skin findings (erythema, induration, and scaling \\[scale\\]) at each of the regions and the extent of area affected. Total sores were calculated scores of the each regions.\n\nWhen the day of the assessment fell on a day on which study product was to be administered, the assessment was performed before the study product was administered.\n\nAs a rule, the PASI score assessments for each patient were performed by the same investigator throughout the study, unless there was a special reason why this was not done (e.g., the investigator changed jobs).\n\nThe number and percentage of patients achieving a 75% improvement in their PASI scores at each assessment time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"16.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"16.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"33.3","spread":null},{"groupId":"OG004","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"50.0","spread":null},{"groupId":"OG004","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"34.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"50.0","spread":null},{"groupId":"OG004","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"53.6","spread":null},{"groupId":"OG002","value":"14.3","spread":null},{"groupId":"OG003","value":"50.0","spread":null},{"groupId":"OG004","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"40.7","spread":null},{"groupId":"OG002","value":"42.9","spread":null},{"groupId":"OG003","value":"33.3","spread":null},{"groupId":"OG004","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"69.2","spread":null},{"groupId":"OG002","value":"28.6","spread":null},{"groupId":"OG003","value":"83.3","spread":null},{"groupId":"OG004","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"42.9","spread":null},{"groupId":"OG003","value":"50.0","spread":null},{"groupId":"OG004","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"42.3","spread":null},{"groupId":"OG002","value":"28.6","spread":null},{"groupId":"OG003","value":"66.7","spread":null},{"groupId":"OG004","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"42.9","spread":null},{"groupId":"OG003","value":"80.0","spread":null},{"groupId":"OG004","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Psoriasis Area and Severity Index (PASI) Score","description":"Score range is 0-72. Higher values represent a worse outcome. The investigator or the subinvestigator examined the head, trunk, and upper and lower limbs, and assessed skin findings (erythema, induration, and scaling \\[scale\\]) at each of the regions and the extent of area affected. Total sores were added scores of the each regions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.70","spread":null},{"groupId":"OG001","value":"12.80","spread":null},{"groupId":"OG002","value":"13.95","spread":null},{"groupId":"OG003","value":"14.70","spread":null},{"groupId":"OG004","value":"22.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.60","spread":null},{"groupId":"OG001","value":"6.20","spread":null},{"groupId":"OG002","value":"8.20","spread":null},{"groupId":"OG003","value":"9.90","spread":null},{"groupId":"OG004","value":"9.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.25","spread":null},{"groupId":"OG001","value":"7.50","spread":null},{"groupId":"OG002","value":"8.20","spread":null},{"groupId":"OG003","value":"4.20","spread":null},{"groupId":"OG004","value":"14.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.40","spread":null},{"groupId":"OG001","value":"4.40","spread":null},{"groupId":"OG002","value":"6.60","spread":null},{"groupId":"OG003","value":"3.70","spread":null},{"groupId":"OG004","value":"3.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.80","spread":null},{"groupId":"OG001","value":"6.60","spread":null},{"groupId":"OG002","value":"6.60","spread":null},{"groupId":"OG003","value":"7.40","spread":null},{"groupId":"OG004","value":"9.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":null},{"groupId":"OG001","value":"3.95","spread":null},{"groupId":"OG002","value":"3.80","spread":null},{"groupId":"OG003","value":"4.80","spread":null},{"groupId":"OG004","value":"3.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.80","spread":null},{"groupId":"OG001","value":"4.70","spread":null},{"groupId":"OG002","value":"4.80","spread":null},{"groupId":"OG003","value":"5.80","spread":null},{"groupId":"OG004","value":"5.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.25","spread":null},{"groupId":"OG001","value":"3.25","spread":null},{"groupId":"OG002","value":"4.20","spread":null},{"groupId":"OG003","value":"2.75","spread":null},{"groupId":"OG004","value":"5.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.70","spread":null},{"groupId":"OG001","value":"4.50","spread":null},{"groupId":"OG002","value":"4.20","spread":null},{"groupId":"OG003","value":"6.05","spread":null},{"groupId":"OG004","value":"4.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":null},{"groupId":"OG001","value":"3.40","spread":null},{"groupId":"OG002","value":"1.80","spread":null},{"groupId":"OG003","value":"3.15","spread":null},{"groupId":"OG004","value":"3.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":null},{"groupId":"OG001","value":"4.70","spread":null},{"groupId":"OG002","value":"2.40","spread":null},{"groupId":"OG003","value":"2.70","spread":null},{"groupId":"OG004","value":"3.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Cleared and Minimal Skin Lesions of Physician Global Assessment (PGA) (Only for Patients With Plaque Psoriasis)","description":"The investigator or the subinvestigator made a global assessment of skin lesions in terms of the degree of erythema, induration, and scaling (scale), using the following 6-point scale (0 to 5). When the day of the assessment fell on a day on which study product was to be administered, the assessment was performed before the study product was administered. As a rule, the PGA for each patient were performed by the same investigator or subinvestigator throughout the study, unless there was a special reason why this was not done (e.g., the investigator or the subinvestigator changed jobs). Outcome measure data table is reported percentage of participants with Cleared and Minimal skin lesions.\n\n0: Cleared, 1: Minimal, 2: Mild, 3: Moderate, 4: Marked, 5: Severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Visual Analog Scaleï¼VASï¼ of Pain Assessment by Subjects (Only for Patients With Psoriatic Arthritis)","description":"From 0 (best) to 100 (worst)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Severity (Only for Patients With Pustular Psoriasis)","description":"From 0 (best) to 17 (worst)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["Double stranded DNA antibody positive","Nasopharyngitis","Headache","Urticaria","Vomiting"]}}}